4 days of the SGLT2 inhibitor lowered the incidence of AKI substantially ...

Dimerix already has a late-stage rare kidney disease asset in FSGS, so adding DMX-652 creates a continuum from acute injury to chronic disease, potentially giving the company more ...

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Acute kidney injury (AKI) as a result of COVID-19 is more deadly in patients in intensive care even ...

Please provide your email address to receive an email when new articles are posted on . Researchers found 13% of patients hospitalized with inflammatory bowel disease had AKI. They also found 15% of ...

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.